Clinical Trial Update: A Phase 1 Positron Emission Tomography Study to Measure Cholesterol 24S-Hydroxylase Target Occupancy of TAK-935 [Phase 1]

View source ↗

Summary

Phase 1 PET imaging study to measure TAK-935 target occupancy in epilepsy. The trial is completed and results were posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• TAK-935

Snippet

Sponsor: Takeda | Conditions: Epilepsy, Molecular Mechanisms of Pharmalogical Action, Protective Agents | Phase 1 | Status: COMPLETED | Results posted: 2017-04-11